Search Results - "Dastani, H.B."

3331 Quality of survival (QoS) concept framework to assess the quality of prolonged life in advanced melanoma (MEL): Principles and application related to treatment with nivolumab (NIVO) by Fallowfield, L, Nadler, E, Abernethy, A.P, Gilloteau, I, Greaney, M, Gater, A, Orsini, L, Subar, M, Dastani, H.B, Lyman, G.H

Get full text

Health Care Resource Use Among People with Multiple Sclerosis by Korelitz, J.J, Dastani, H.B, Li, S.X, Xu, Y, Wilson, J.W, Gustavson, B.K

Get full text

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study by Long, G.V., Atkinson, V., Ascierto, P.A., Robert, C., Hassel, J.C., Rutkowski, P., Savage, K.J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H.B., Waxman, I.M., Abernethy, A.P.

“…Nivolumab has shown significant survival benefit and a favorable safety profile compared with dacarbazine chemotherapy among treatment-naïve patients with…”
Get full text

Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): results of a phase III study (CheckMate 066) by Long, G.V., Atkinson, V., Ascierto, P.A., Robert, C., Hassel, J.C., Rutkowski, P., Savage, K.J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H.B., Waxman, I., Abernethy, A.P.

Get full text

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension by Signorovitch, J., Zhang, J., Wu, E.Q., Latremouille-Viau, D., Yu, A.P., Dastani, H.B., Kahler, K.H.

“…Abstract Background: The approaching availability of lower-cost generic angiotensin receptor blockers (ARBs) may affect formulary policies for patients…”
Get full text